Exosomes derived from mesenchymal stem cells

Bo Yu, Xiaomin Zhang, Xiaorong Li, Bo Yu, Xiaomin Zhang, Xiaorong Li

Abstract

The functional mechanisms of mesenchymal stem cells (MSCs) have become a research focus in recent years. Accumulating evidence supports the notion that MSCs act in a paracrine manner. Therefore, the biological factors in conditioned medium, including exosomes and soluble factors, derived from MSC cultures are being explored extensively. The results from most investigations show that MSC-conditioned medium or its components mediate some biological functions of MSCs. Several studies have reported that MSC-derived exosomes have functions similar to those of MSCs, such as repairing tissue damage, suppressing inflammatory responses, and modulating the immune system. However, the mechanisms are still not fully understood and the results remain controversial. Compared with cells, exosomes are more stable and reservable, have no risk of aneuploidy, a lower possibility of immune rejection following in vivo allogeneic administration, and may provide an alternative therapy for various diseases. In this review, we summarize the properties and biological functions of MSC-derived exosomes and discuss the related mechanisms.

References

    1. Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C. Vesicle formation during reticulocyte maturation Association of plasma membrane activities with released vesicles (exosomes) J. Biol. Chem. 1987;19:9412–9420.
    1. Katsha A.M., Ohkouchi S., Xin H., Kanehira M., Sun R., Nukiwa T., Saijo Y. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol. Ther. 2011;1:196–203.
    1. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Quinn G., Okochi H., Ochiya T. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology. 2007;1:219–228.
    1. Lai R.C., Arslan F., Tan S.S., Tan B., Choo A., Lee M.M., Chen T.S., Teh B.J., Eng J.K., Sidik H., et al. Derivation and characterization of human fetal MSCs: An alternative cell source for large-scale production of cardioprotective microparticles. J. Mol. Cell. Cardiol. 2010;6:1215–1224.
    1. Sato T., Iso Y., Uyama T., Kawachi K., Wakabayashi K., Omori Y., Soda T., Shoji M., Koba S., Yokoyama S., et al. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. Lab. Investig. 2011;4:553–564.
    1. Aurich H., Sgodda M., Kaltwasser P., Vetter M., Weise A., Liehr T., Brulport M., Hengstler J.G., Dollinger M.M., Fleig W.E., et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;4:570–581.
    1. Matsuse D., Kitada M., Kohama M., Nishikawa K., Makinoshima H., Wakao S., Fujiyoshi Y., Heike T., Nakahata T., Akutsu H., et al. Human umbilical cord-derived mesenchymal stromal cells differentiate into functional Schwann cells that sustain peripheral nerve regeneration. J. Neuropathol. Exp. Neurol. 2010;9:973–985.
    1. Curley G.F., Ansari B., Hayes M., Devaney J., Masterson C., Ryan A., Barry F., O’Brien T., Toole D.O., Laffey J.G. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology. 2013;4:924–932.
    1. Schuleri K.H., Feigenbaum G.S., Centola M., Weiss E.S., Zimmet J.M., Turney J., Kellner J., Zviman M.M., Hatzistergos K.E., Detrick B., et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur. Heart J. 2009;22:2722–2732.
    1. Reinshagen H., Auw-Haedrich C., Sorg R.V., Boehringer D., Eberwein P., Schwartzkopff J., Sundmacher R., Reinhard T. Corneal surface reconstruction using adult mesenchymal stem cells in experimental limbal stem cell deficiency in rabbits. Acta Ophthalmol. 2011;8:741–748.
    1. Xue Q., Luan X.Y., Gu Y.Z., Wu H.Y., Zhang G.B., Yu G.H., Zhu H.T., Wang M., Dong W., Geng Y.J., et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev. 2010;1:27–38.
    1. Shi M., Liu Z.W., Wang F.S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin. Exp. Immunol. 2011;1:1–8.
    1. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V., et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;1:367–372.
    1. Zhang X., Jiao C., Zhao S. Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev. 2009;4:402–409.
    1. Jia Z., Jiao C., Zhao S., Li X., Ren X., Zhang L., Han Z.C., Zhang X. Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model. Exp. Eye Res. 2012;102:44–49.
    1. Li G., Yuan L., Ren X., Nian H., Zhang L., Han Z.C., Li X., Zhang X. The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis. Clin. Exp. Immunol. 2013;173:28–37.
    1. Zhang X., Ren X., Li G., Jiao C., Zhang L., Zhao S., Wang J., Han Z.C., Li X. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Investig. Ophthalmol. Vis. Sci. 2011;6:3143–3152.
    1. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., Kooy-Winkelaar E.M., Koning F., Zwaginga J.J., Fidder H.H., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: Results of a phase I study. Gut. 2010;12:1662–1669.
    1. Johnson T.V., Bull N.D., Hunt D.P., Marina N., Tomarev S.I., Martin K.R. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 2010;4:2051–2059.
    1. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Ren. Physiol. 2005;1:F31–F42.
    1. Harding C., Heuser J., Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 1983;2:329–339.
    1. Record M., Subra C., Silvente-Poirot S., Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011;10:1171–1182.
    1. Saunderson S.C., Schuberth P.C., Dunn A.C., Miller L., Hock B.D., MacKay P.A., Koch N., Jack R.W., McLellan A.D. Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. J. Immunol. 2008;12:8146–8152.
    1. Chaput N., Thery C. Exosomes: Immune properties and potential clinical implementations. Semin. Immunopathol. 2011;5:419–440.
    1. Breakefield X.O., Frederickson R.M., Simpson R.J. Gesicles: Microvesicle “cookies” for transient information transfer between cells. Mol. Ther. 2011;9:1574–1576.
    1. Thery C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006;30:1–29.
    1. Sokolova V., Ludwig A.K., Hornung S., Rotan O., Horn P.A., Epple M., Giebel B. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf. B. 2011;1:146–150.
    1. Taylor D.D., Lyons K.S., Gercel-Taylor C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol. Oncol. 2002;3:443–448.
    1. Cheruvanky A., Zhou H., Pisitkun T., Kopp J.B., Knepper M.A., Yuen P.S., Star R.A. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am. J. Physiol. Ren. Physiol. 2007;5:F1657–F1661.
    1. Mokarizadeh A., Delirezh N., Morshedi A., Mosayebi G., Farshid A.A., Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol. Lett. 2012;147:47–54.
    1. Munich S., Sobo-Vujanovic A., Buchser W.J., Beer-Stolz D., Vujanovic N.L. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012;7:1074–1083.
    1. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: Current knowledge of their composition biological functions and diagnostic and therapeutic potentials. Biochim. Biophys. Acta. 2012;7:940–948.
    1. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009;8:581–593.
    1. Zoller M. Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer. 2009;1:40–55.
    1. Raimondo F., Morosi L., Chinello C., Magni F., Pitto M. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics. 2011;4:709–720.
    1. Chavez-Munoz C., Kilani R.T., Ghahary A. Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes. J. Cell. Physiol. 2009;1:221–231.
    1. Kriebel P.W., Barr V.A., Rericha E.C., Zhang G., Parent C.A. Collective cell migration requires vesicular trafficking for chemoattractant delivery at the trailing edge. J. Cell Biol. 2008;5:949–961.
    1. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., Curry W.J., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008;12:1470–1476.
    1. Kosaka N., Izumi H., Sekine K., Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence. 2010;1:1–8.
    1. Pegtel D.M., van de Garde M.D., Middeldorp J.M. Viral miRNAs exploiting the endosomal–exosomal pathway for intercellular cross-talk and immune evasion. Biochim. Biophys. Acta. 2011;1809:715–721.
    1. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008;5:619–624.
    1. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;10:997–1006.
    1. Takata K., Matsuzaki T., Tajika Y., Ablimit A., Hasegawa T. Localization and trafficking of aquaporin 2 in the kidney. Histochem. Cell Biol. 2008;2:197–209.
    1. Nilsson J., Skog J., Nordstrand A., Baranov V., Mincheva-Nilsson L., Breakefield X.O., Widmark A. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br. J. Cancer. 2009;10:1603–1607.
    1. Subra C., Grand D., Laulagnier K., Stella A., Lambeau G., Paillasse M., de Medina P., Monsarrat B., Perret B., Silvente-Poirot S., et al. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res. 2010;8:2105–2120.
    1. Heijnen H.F., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood. 1999;11:3791–3799.
    1. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El O.R., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;3:214–222.
    1. Yeo R.W., Lai R.C., Zhang B., Tan S.S., Yin Y., Teh B.J., Lim S.K. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 2013;3:336–341.
    1. Lai R.C., Tan S.S., Teh B.J., Sze S.K., Arslan F., de Kleijn D.P., Choo A., Lim S.K. Proteolytic potential of the MSC exosome proteome: Implications for an exosome-mediated delivery of therapeutic proteasome. Int. J. Proteomics. 2012;2012:971907.
    1. Carayon K., Chaoui K., Ronzier E., Lazar I., Bertrand-Michel J., Roques V., Balor S., Terce F., Lopez A., Salome L., et al. Proteolipidic composition of exosomes changes during reticulocyte maturation. J. Biol. Chem. 2011;39:34426–34439.
    1. Chen T.S., Lai R.C., Lee M.M., Choo A.B., Lee C.N., Lim S.K. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;1:215–224.
    1. Reis L.A., Borges F.T., Simoes M.J., Borges A.A., Sinigaglia-Coimbra R., Schor N. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One. 2012;9:e44092.
    1. Xin H., Li Y., Buller B., Katakowski M., Zhang Y., Wang X., Shang X., Zhang Z.G., Chopp M. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012;7:1556–1564.
    1. Karp J.M., Leng T.G. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;3:206–216.
    1. Timmers L., Lim S.K., Arslan F., Armstrong J.S., Hoefer I.E., Doevendans P.A., Piek J.J., El O.R., Choo A., Lee C.N., et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2007;2:129–137.
    1. Lai R.C., Chen T.S., Lim S.K. Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease. Regen. Med. 2011;4:481–492.
    1. Morigi M., Imberti B., Zoja C., Corna D., Tomasoni S., Abbate M., Rottoli D., Angioletti S., Benigni A., Perico N., et al. Mesenchymal stem cells are renotropic helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol. 2004;7:1794–1804.
    1. Lin F., Moran A., Igarashi P. Intrarenal cells not bone marrow-derived cells are the major source for regeneration in postischemic kidney. J. Clin. Investig. 2005;7:1756–1764.
    1. Bi B., Schmitt R., Israilova M., Nishio H., Cantley L.G. Stromal cells protect against acute tubular injury via an endocrine effect. J. Am. Soc. Nephrol. 2007;9:2486–2496.
    1. Deregibus M.C., Tetta C., Camussi G. The dynamic stem cell microenvironment is orchestrated by microvesicle-mediated transfer of genetic information. Histol. Histopathol. 2010;3:397–404.
    1. Porada C.D., Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv. Drug Deliv. Rev. 2010;12:1156–1166.
    1. Zhang B., Yin Y., Lai R.C., Tan S.S., Choo A.B., Lim S.K. Mesenchymal stem cell secretes immunologically active exosomes. Stem Cells Dev. 2014 doi: 10.1089/scd.2013.0479.
    1. Rahman M.J., Regn D., Bashratyan R., Dai Y.D. Exosomes released by islet-derived mesenchymal stem cells trigger autoimmune responses in NOD mice. Diabetes. 2014 doi: 10.2337/db13-0859.
    1. Zhu W., Huang L., Li Y., Zhang X., Gu J., Yan Y., Xu X., Wang M., Qian H., Xu W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012;1:28–37.
    1. Zhu W., Huang L., Li Y., Qian H., Shan X., Yan Y., Mao F., Wu X., Xu W.R. Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle. 2011;18:3198–3207.
    1. Lee J.K., Park S.R., Jung B.K., Jeon Y.K., Lee Y.S., Kim M.K., Kim Y.G., Jang J.Y., Kim C.W. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 2013;12:e84256.
    1. Xin H., Li Y., Cui Y., Yang J.J., Zhang Z.G., Chopp M. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. Blood Flow Metab. 2013;11:1711–1715.
    1. Katsuda T., Tsuchiya R., Kosaka N., Yoshioka Y., Takagaki K., Oki K., Takeshita F., Sakai Y., Kuroda M., Ochiya T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 2013;3:1197.
    1. Lai R.C., Yeo R.W., Tan K.H., Lim S.K. Exosomes for drug delivery—A novel application for the mesenchymal stem cell. Biotechnol. Adv. 2013;5:543–551.
    1. Yu L., Yang F., Jiang L., Chen Y., Wang K., Xu F., Wei Y., Cao X., Wang J., Cai Z. Exosomes with membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur. J. Immunol. 2013;9:2461–2472.
    1. Kim S.H., Bianco N.R., Shufesky W.J., Morelli A.E., Robbins P.D. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 2007;4:2242–2249.
    1. Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 2008;10:711–715.
    1. Cao Z., Zhang G., Wang F., Liu H., Liu L., Han Y., Zhang J., Yuan J. Protective effects of mesenchymal stem cells with CXCR4 up-regulation in a rat renal transplantation model. PLoS One. 2013;12:e82949.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다